RCCP1
MCID: RNL065
MIFTS: 79

Renal Cell Carcinoma, Papillary, 1 (RCCP1)

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Cell Carcinoma, Papillary, 1

MalaCards integrated aliases for Renal Cell Carcinoma, Papillary, 1:

Name: Renal Cell Carcinoma, Papillary, 1 57 29 6
Papillary Renal Cell Carcinoma 12 20 58 29 6 15 17 71
Papillary Renal Cell Carcinoma, Sporadic 6 44 71
Papillary Renal Cell Adenocarcinoma 20 58
Renal Cell Carcinoma, Papillary 57 13
Rccp 20 73
Renal Cell Carcinoma, Papillary, 1, Familial and Somatic 57
Papillary Renal Cell Carcinoma, Bilateral - 20
Papillary Renal Cell Carcinoma, Familial - 20
Papillary Renal Cell Carcinoma, Multiple - 20
Papillary Renal Cell Carcinoma, Sporadic - 20
Hereditary Papillary Renal Cell Carcinoma 58
Carcinoma, Renal Cell, Papillary, Type 1 39
Sporadic Papillary Renal Cell Carcinoma 12
Papillary Renal Carcinoma, Malignant - 20
Type 1 Papillary Renal Cell Carcinoma 71
Hereditary Papillary Renal Carcinoma 71
Chromophilic Renal Cell Carcinoma 73
Chromophil Carcinoma of Kidney 12
Renal Cell Carcinoma Papillary 73
Papillary Kidney Carcinoma 12
Renal Cell Carcinoma 71
Renal Adenocarcinoma 20
Rccp1 57
Hprcc 58
Prcc 73

Characteristics:

Orphanet epidemiological data:

58
hereditary papillary renal cell carcinoma
Inheritance: Autosomal dominant; Age of onset: Adult;

HPO:

31
renal cell carcinoma, papillary, 1:
Inheritance autosomal dominant inheritance somatic mutation
Onset and clinical course incomplete penetrance


Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4465
OMIM® 57 605074
NCIt 50 C27890 C6975
SNOMED-CT 67 4797003
MESH via Orphanet 45 C538614
ICD10 via Orphanet 33 C64
UMLS via Orphanet 72 C0879257 C1306837 C2931899
SNOMED-CT via HPO 68 124975008 263681008
UMLS 71 C0007134 C0879257 C1306837 more

Summaries for Renal Cell Carcinoma, Papillary, 1

OMIM® : 57 Hereditary papillary renal cell carcinoma is characterized by the development of multiple, bilateral papillary renal tumors (Zbar et al., 1995). The transmission pattern is consistent with autosomal dominant inheritance with incomplete penetrance. Papillary renal cell carcinoma is histologically and genetically distinct from 2 other forms of inherited renal carcinoma, von Hippel Lindau disease (193300), caused by mutation in the VHL gene (608537) on chromosome 3, and a form associated with the chromosome translocation t(3;8), as described by Cohen et al. (1979). Bodmer et al. (2002) reviewed the molecular genetics of familial and nonfamilial cases of renal cell carcinoma, including the roles of VHL, MET, and translocations involving chromosomes 1, 3, and X. For background information and a discussion of genetic heterogeneity of nonpapillary renal cell carcinoma, see RCC (144700). See also a hereditary syndrome of predisposition to uterine leiomyomas and papillary renal cell carcinoma (HLRCC; 150800) caused by germline mutation in the FH gene (136850). (605074) (Updated 05-Mar-2021)

MalaCards based summary : Renal Cell Carcinoma, Papillary, 1, also known as papillary renal cell carcinoma, is related to clear cell papillary renal cell carcinoma and kidney benign neoplasm, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Papillary, 1 is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nicotine and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and bone, and related phenotypes are papillary renal cell carcinoma and Decreased viability

Disease Ontology : 12 A renal cell carcinoma that is characterized by the development of multiple, bilateral papillary renal tumors.

GARD : 20 Papillary renal cell carcinoma (PRCC) is a type of cancer that occurs in the kidneys. It accounts for about 10-15% of all renal cell carcinomas.Renal cell carcinomas are a type of kidney cancer that develop in the lining of very small tubes (tubules) in the kidney.The term "papillary" describes the finger-like projections that can be found in most of the tumors. PRCC can be divided into two types: type 1, which is more common and usually grows more slowly and type 2, which are usually more aggressive .Though the exact cause of papillary renal cell carcinoma is unknown, smoking, obesity, and genetic predisposition conditions (such as hereditary leiomyomatosis and renal cell cancer) may contribute to the development of this type of cancer. Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.

UniProtKB/Swiss-Prot : 73 Renal cell carcinoma papillary: A subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium.

Related Diseases for Renal Cell Carcinoma, Papillary, 1

Diseases related to Renal Cell Carcinoma, Papillary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 440)
# Related Disease Score Top Affiliating Genes
1 clear cell papillary renal cell carcinoma 32.9 VHL MITF
2 kidney benign neoplasm 32.2 RHEB PRCC MTOR
3 alveolar soft part sarcoma 32.1 PRCC MTOR MET
4 kidney cancer 32.0 VHL TP53 PTEN PIK3CA MTOR MET
5 adenoma 31.8 VHL TP53 PIK3CA CDKN2A
6 von hippel-lindau syndrome 31.3 VHL MET LOC107303340 ELOC
7 gastrointestinal stromal tumor 31.2 TP53 PTEN FGFR3 ERBB2 CDKN2A
8 collecting duct carcinoma 31.2 VHL ERBB2 CDKN2A
9 transitional cell carcinoma 31.1 TP53 PTEN HRAS FGFR3 ERBB2 CDKN2A
10 adenocarcinoma 31.0 TP53 PTEN PIK3CA MET HRAS FGFR3
11 pheochromocytoma 30.9 VHL MITF LOC107303340 HRAS ERBB2 CDKN2A
12 lynch syndrome 30.9 TP53 PTEN PIK3CA NRAS HRAS FGFR3
13 tuberous sclerosis 1 30.8 TP53 RHEB PTEN PIK3CA MTOR
14 liposarcoma 30.8 TP53 PTEN PIK3CA CDKN2A
15 cowden syndrome 1 30.8 TP53 RHEB PTEN PIK3CA MTOR
16 rectum adenocarcinoma 30.8 TP53 PIK3CA HRAS ERBB2
17 small cell cancer of the lung 30.8 TP53 PTEN PIK3CA CDKN2A
18 cholangiocarcinoma 30.8 TP53 PIK3CA MTOR MET ERBB2
19 tuberous sclerosis 30.8 VHL TP53 RHEB PTEN PIK3CA MTOR
20 hemangioma 30.8 VHL TP53 PTEN MTOR
21 clear cell renal cell carcinoma 30.8 VHL TP53 PTEN MTOR MET
22 colorectal adenocarcinoma 30.7 TP53 PTEN HRAS ERBB2 CDKN2A ATM
23 childhood kidney cell carcinoma 30.7 PRCC MITF
24 adenoid cystic carcinoma 30.7 TP53 SF3B1 PTEN PIK3CA HRAS ERBB2
25 lung cancer susceptibility 3 30.6 TP53 PIK3CA NRAS NFE2L2 MET HRAS
26 renal cell carcinoma, nonpapillary 30.6 VHL TP53 SF3B2 SF3B1 RHEB PTEN
27 prostate cancer 30.5 TP53 PTEN PIK3CA NFE2L2 MTOR MET
28 sarcoma 30.4 TP53 PIK3CA NRAS MTOR HRAS FGFR3
29 exanthem 30.4 MTOR HRAS ERBB2
30 in situ carcinoma 30.4 TP53 PTEN PIK3CA HRAS ERBB2 CDKN2A
31 mucinous adenocarcinoma 30.3 TP53 ERBB2 CDKN2A
32 hepatocellular carcinoma 30.2 TP53 SF3B2 SF3B1 PTEN PIK3CA NRAS
33 renal cell carcinoma, xp11-associated 11.5
34 metanephric adenoma 11.3
35 hereditary leiomyomatosis and renal cell cancer 11.0
36 hawkinsinuria 10.9
37 nephrogenic adenofibroma 10.9
38 epithelial predominant wilms' tumor 10.9
39 oncocytoma 10.6
40 parameningeal embryonal rhabdomyosarcoma 10.6 TP53 PIK3CA NRAS
41 ovarian clear cell adenocarcinoma 10.6 TP53 PIK3CA MTOR MET
42 endometrioid ovary carcinoma 10.6 TP53 PTEN PIK3CA
43 penile benign neoplasm 10.6 TP53 PIK3CA CDKN2A
44 thyroid hurthle cell adenoma 10.6 PTEN PIK3CA
45 hemimegalencephaly 10.6 RHEB PIK3CA MTOR
46 ovarian carcinosarcoma 10.6 TP53 PIK3CA ERBB2
47 malignant spiradenoma 10.6 TP53 PIK3CA MTOR CDKN2A
48 chromosomal triplication 10.6
49 ovarian clear cell carcinoma 10.6 TP53 PTEN PIK3CA MTOR
50 vulva squamous cell carcinoma 10.6 TP53 PIK3CA CDKN2A

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Papillary, 1:



Diseases related to Renal Cell Carcinoma, Papillary, 1

Symptoms & Phenotypes for Renal Cell Carcinoma, Papillary, 1

Human phenotypes related to Renal Cell Carcinoma, Papillary, 1:

31
# Description HPO Frequency HPO Source Accession
1 papillary renal cell carcinoma 31 HP:0006766

Clinical features from OMIM®:

605074 (Updated 05-Mar-2021)

UMLS symptoms related to Renal Cell Carcinoma, Papillary, 1:


flank pain

GenomeRNAi Phenotypes related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

26 (show top 50) (show all 67)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.69 MTOR PIK3CA HRAS
2 Decreased viability GR00055-A-2 10.69 MTOR PIK3CA HRAS
3 Decreased viability GR00221-A-1 10.69 CDKN2A MTOR PIK3CA FGFR3 HRAS NRAS
4 Decreased viability GR00221-A-2 10.69 PIK3CA FGFR3 HRAS VHL
5 Decreased viability GR00221-A-3 10.69 ATM CDKN2A ERBB2 FGFR3 HRAS NRAS
6 Decreased viability GR00221-A-4 10.69 ATM CDKN2A ERBB2 MTOR PIK3CA
7 Decreased viability GR00249-S 10.69 FGFR3 VHL
8 Decreased viability GR00301-A 10.69 VHL
9 Decreased viability GR00342-S-1 10.69 MTOR
10 Decreased viability GR00342-S-2 10.69 MTOR
11 Decreased viability GR00386-A-1 10.69 RHEB
12 Decreased viability GR00402-S-2 10.69 PIK3CA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.45 MTOR RHEB
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.45 PIK3CA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.45 PTEN
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.45 PIK3CA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.45 ATM MTOR PIK3CA RHEB
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.45 PIK3CA PRCC
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.45 PRCC
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.45 MTOR RHEB
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.45 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.45 PIK3CA
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.45 PRCC
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 10.45 ATM
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-215 10.45 ATM
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.45 PIK3CA RHEB
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.45 MTOR PIK3CA RHEB
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.45 PIK3CA
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.45 MTOR PIK3CA
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 10.45 RHEB
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.45 RHEB
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.45 MTOR
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 10.45 ATM
34 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10.26 FGFR3 MET
35 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.26 RHEB
36 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.26 MET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.26 FGFR3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.26 MET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.26 FGFR3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.26 PTEN
41 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.26 PTEN
42 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.26 ERBB2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.26 ERBB2 PTEN
44 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.26 MET
45 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.26 MET
46 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.26 MET
47 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.26 ERBB2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.26 PTEN
49 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.26 NRAS
50 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.26 ERBB2

MGI Mouse Phenotypes related to Renal Cell Carcinoma, Papillary, 1:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.46 ATM CDKN2A ERBB2 FGFR3 HRAS MET
2 cellular MP:0005384 10.45 ATM CDKN2A ERBB2 FGFR3 MET MITF
3 growth/size/body region MP:0005378 10.44 ATM CDKN2A ERBB2 FGFR3 HRAS MET
4 behavior/neurological MP:0005386 10.43 ATM CDKN2A ERBB2 FGFR3 HRAS MET
5 cardiovascular system MP:0005385 10.42 ATM CDKN2A ERBB2 HRAS MET MTOR
6 embryo MP:0005380 10.4 ATM CDKN2A ERBB2 MET MITF MTOR
7 mortality/aging MP:0010768 10.4 ATM CDKN2A ERBB2 FGFR3 HRAS MET
8 endocrine/exocrine gland MP:0005379 10.39 ATM CDKN2A ERBB2 HRAS MET MITF
9 immune system MP:0005387 10.39 ATM CDKN2A FGFR3 MET MITF MTOR
10 integument MP:0010771 10.31 ATM CDKN2A ERBB2 FGFR3 HRAS MITF
11 digestive/alimentary MP:0005381 10.29 CDKN2A ERBB2 FGFR3 HRAS MET NFE2L2
12 craniofacial MP:0005382 10.25 ERBB2 FGFR3 HRAS MET MITF NFE2L2
13 nervous system MP:0003631 10.25 ATM CDKN2A ERBB2 FGFR3 HRAS MET
14 neoplasm MP:0002006 10.23 ATM CDKN2A ERBB2 FGFR3 HRAS MET
15 muscle MP:0005369 10.18 CDKN2A ERBB2 HRAS MET MTOR PIK3CA
16 normal MP:0002873 10.15 ERBB2 FGFR3 HRAS MET MITF MTOR
17 limbs/digits/tail MP:0005371 10.13 ERBB2 FGFR3 MET MITF NRAS PTEN
18 liver/biliary system MP:0005370 10.11 CDKN2A MET MITF NFE2L2 NRAS PTEN
19 no phenotypic analysis MP:0003012 10.06 CDKN2A FGFR3 HRAS MET MITF MTOR
20 renal/urinary system MP:0005367 9.97 FGFR3 HRAS MET MITF MTOR NFE2L2
21 reproductive system MP:0005389 9.96 ATM CDKN2A ERBB2 FGFR3 MITF PIK3CA
22 respiratory system MP:0005388 9.81 CDKN2A ERBB2 FGFR3 HRAS MET MTOR
23 skeleton MP:0005390 9.77 CDKN2A ERBB2 FGFR3 HRAS MITF MTOR
24 vision/eye MP:0005391 9.28 CDKN2A FGFR3 MET MITF NRAS PIK3CA

Drugs & Therapeutics for Renal Cell Carcinoma, Papillary, 1

Drugs for Renal Cell Carcinoma, Papillary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 345)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Aldesleukin Approved Phase 4 110942-02-4, 85898-30-2
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4
Ipilimumab Approved Phase 4 477202-00-9
5
nivolumab Approved Phase 4 946414-94-4
6
Gemcitabine Approved Phase 4 95058-81-4 60750
7 Central Nervous System Stimulants Phase 4
8 Nicotinic Agonists Phase 4
9 Cholinergic Agents Phase 4
10 Psychotropic Drugs Phase 4
11 Dopamine Agents Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Dopamine Uptake Inhibitors Phase 4
14 Antidepressive Agents Phase 4
15 Antineoplastic Agents, Immunological Phase 4
16
Sunitinib Approved, Investigational Phase 3 341031-54-7, 557795-19-4 5329102
17
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 437-38-7 3345
19
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
20
Bupivacaine Approved, Investigational Phase 2, Phase 3 38396-39-3, 2180-92-9 2474
21
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
22
tannic acid Approved Phase 2, Phase 3 1401-55-4
23
Fluorouracil Approved Phase 3 51-21-8 3385
24
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
25
Promethazine Approved, Investigational Phase 3 60-87-7 4927
26
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
27
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
28
Peginterferon alfa-2a Approved, Investigational Phase 2, Phase 3 198153-51-4 5360545
29
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
30
Durvalumab Approved, Investigational Phase 3 1428935-60-7
31
Povidone-iodine Approved Phase 3 25655-41-8
32
Povidone Approved Phase 3 9003-39-8 131751496
33
Denosumab Approved Phase 3 615258-40-7
34
Lenvatinib Approved, Investigational Phase 3 417716-92-8
35
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
36
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
37
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
38
Tremelimumab Investigational Phase 3 745013-59-6
39
Abexinostat Investigational Phase 3 783355-60-2
40 Anti-Infective Agents Phase 2, Phase 3
41 Antiviral Agents Phase 2, Phase 3
42 Sympatholytics Phase 2, Phase 3
43 interferons Phase 2, Phase 3
44 Calcium, Dietary Phase 3
45 Interferon-alpha Phase 2, Phase 3
46 Anti-Bacterial Agents Phase 3
47 Histamine Antagonists Phase 3
48 Histamine H1 Antagonists Phase 3
49 Interferon alpha-2 Phase 2, Phase 3
50 Contraceptives, Oral Phase 3

Interventional clinical trials:

(show top 50) (show all 975)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
4 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
5 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
6 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
7 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
8 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
9 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Completed NCT02555748 Phase 4 Pazopanib;Sunitinib
10 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
11 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
12 ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial Recruiting NCT02399124 Phase 4
13 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
14 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Active, not recruiting NCT02596035 Phase 4 Nivolumab
15 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
16 A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India Not yet recruiting NCT04513522 Phase 4
17 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
18 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
19 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
20 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
21 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
22 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy Unknown status NCT01865747 Phase 3 Cabozantinib tablets;Everolimus (Afinitor) tablets
23 Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib Unknown status NCT00930033 Phase 3
24 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
25 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
26 Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma Completed NCT02030717 Phase 2, Phase 3 klonidin;epidural anesthesia
27 An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192 Completed NCT00387764 Phase 3 pazopanib
28 A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy Completed NCT01235962 Phase 3 pazopanib;placebo;pazopanib;placebo
29 A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma. Completed NCT01064310 Phase 3 pazopanib;sunitinib
30 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2
31 Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma Completed NCT00631371 Phase 3 Bevacizumab;Temsirolimus;Bevacizumab;Interferon-Alfa 9MU
32 An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma Completed NCT00478114 Phase 3 sorafenib
33 Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma Completed NCT00606866 Phase 3 placebo;Sorafenib;Sorafenib
34 An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies Completed NCT01223027 Phase 3 Dovitinib;Sorafenib
35 ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma Completed NCT00326898 Phase 3 Sorafenib Tosylate;Sunitinib Malate
36 A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma Completed NCT00732914 Phase 3 Sunitinib (Sutent);Sorafenib (Nexavar)
37 A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma Completed NCT00033904 Phase 3 autologous human tumor-derived HSPPC-96
38 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor Completed NCT00410124 Phase 3 RAD001;Placebo
39 PERCY QUATTRO: Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis Completed NCT00291369 Phase 3 Interleukin-2;Interferon alfa;medroxyprogesterone acetate
40 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1) Completed NCT01030783 Phase 3 tivozanib (AV-951);Sorafenib
41 A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma Completed NCT01265901 Phase 3 Sunitinib;Cyclophosphamide;IMA901
42 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
43 Zirconium-89-girentuximab PET/CT Imaging in Patients Suspected of Primary or Relapse Clear Cell Renal Cell Carcinoma: The Impact on Clinical Decision Making. Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
44 A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma. Completed NCT00420888 Phase 2, Phase 3 ABR-217620/naptumomab estafenatox;IFN-alpha
45 An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301). Completed NCT01076010 Phase 3 Tivozanib;Sorafenib
46 A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy Completed NCT00474786 Phase 3 Sorafenib;temsirolimus (Torisel)
47 Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma Completed NCT01613846 Phase 3 Sorafenib+Pazopanib;Pazopanib+Sorafenib
48 Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy Completed NCT01265810 Phase 3
49 Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma Completed NCT00018941 Phase 3
50 A RANDOMIZED PHASE II TRIAL OF INTERFERON ALPHA-2A WITH AND WITHOUT 13-CIS RETINOIC ACID IN PATIENTS WITH PROGRESSIVE MEASURABLE METASTATIC RENAL CELL CARCINOMA. Amendment Protocol: Extension to a Randomized Phase III Trial Completed NCT00002737 Phase 3 chemotherapy;isotretinoin

Search NIH Clinical Center for Renal Cell Carcinoma, Papillary, 1

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide

Cochrane evidence based reviews: papillary renal cell carcinoma, sporadic

Genetic Tests for Renal Cell Carcinoma, Papillary, 1

Genetic tests related to Renal Cell Carcinoma, Papillary, 1:

# Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Papillary, 1 29 MET PRCC
2 Papillary Renal Cell Carcinoma 29

Anatomical Context for Renal Cell Carcinoma, Papillary, 1

MalaCards organs/tissues related to Renal Cell Carcinoma, Papillary, 1:

40
Kidney, Endothelial, Bone, T Cells, Thyroid, Prostate, Lymph Node

Publications for Renal Cell Carcinoma, Papillary, 1

Articles related to Renal Cell Carcinoma, Papillary, 1:

(show top 50) (show all 1085)
# Title Authors PMID Year
1
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. 57 6
9731534 1998
2
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. 57 6
9140397 1997
3
A molecular classification of papillary renal cell carcinoma. 57 61
15994935 2005
4
Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. 57 61
12647800 2003
5
Mapping the papillary renal cell carcinoma gene between loci D17S787 and D17S1799 on chromosome 17q21.32. 57 61
10616219 1999
6
The Heidelberg classification of renal cell tumours. 57 61
9390023 1997
7
Hereditary papillary renal cell carcinoma: clinical studies in 10 families. 57 61
7853572 1995
8
Hereditary papillary renal cell carcinoma. 57 61
8308957 1994
9
Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. 61 57
1000477 1976
10
Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. 57
21404119 2011
11
Renal-cell carcinoma. 57
16339096 2005
12
Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. 57
12837690 2003
13
Understanding familial and non-familial renal cell cancer. 57
12351585 2002
14
High incidence of cancer in a family segregating a mutation of the ATM gene: possible role of ATM heterozygosity in cancer. 6
10571946 1999
15
Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. 57
9715275 1998
16
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. 6
9563489 1998
17
Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. 6
7784063 1995
18
Molecular cytogenetics of renal cell tumors. 57
8109322 1993
19
Cytogenetics of papillary renal cell tumors. 57
1958590 1991
20
Hereditary renal-cell carcinoma associated with a chromosomal translocation. 57
470981 1979
21
Advances in the Characterization of Clear Cell Papillary Renal Cell Carcinoma: Identifying the Sheep in Wolf's Clothing. 61
33579573 2021
22
Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model. 61
33539630 2021
23
Clinical characteristics and treatments of hereditary leiomyomatosis renal cell carcinoma: two case reports and literature review. 61
32932527 2021
24
Routine or enhanced imaging to differentiate between type 1 and type 2 papillary renal cell carcinoma. 61
33092815 2021
25
Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. 61
33527590 2021
26
Cabozantinib: a new first-line option for papillary renal cell carcinoma? 61
33592177 2021
27
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. 61
33592176 2021
28
Evaluation of Human Kidney Injury Molecule 1 (hKIM-1) Expression in Tumors From Various Organs by Messenger RNA In Situ Hybridization. 61
33608720 2021
29
Multi-disciplinary team conference clarifies bosniak classification of complex renal cysts. 61
33307952 2021
30
Clear cell papillary renal cell carcinoma: an update after 15 years. 61
33223139 2021
31
A case of the world's largest renal cell carcinoma. 61
33426498 2021
32
An immune-related lncRNA prognostic model in papillary renal cell carcinoma: A lncRNA expression analysis. 61
32979493 2021
33
Overlapping immunohistochemical features of adenocarcinoma of the nonpigmented ciliary body epithelium and renal cell carcinoma. 61
33529584 2021
34
Etiologic heterogeneity of clear-cell and papillary renal cell carcinoma in the Netherlands Cohort Study. 61
32638386 2021
35
The effect of the papillary renal cell carcinoma subtype on oncological outcomes. 61
33273677 2020
36
A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma. 61
33371886 2020
37
Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report. 61
32458743 2020
38
[Metastatic renal cell carcinoma: a clinicopathological analysis of 196 cases]. 61
33287509 2020
39
Clinicopathological and Molecular Characterization of Papillary Renal Neoplasm with Reverse Polarity and Its Renal Papillary Adenoma Analogue. 61
33351968 2020
40
Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma. 61
33141518 2020
41
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC): Report of a Family Pedigree. 61
32703534 2020
42
Overexpression of enolase 2 is associated with worsened prognosis and increased glycikolysis in papillary renal cell carcinoma. 61
33135164 2020
43
Hemosiderin deposition in papillary renal cell carcinoma and its potential to mask enhancement on MRI: analysis of 110 cases. 61
32518984 2020
44
Prognostic models in papillary renal cell carcinoma. 61
33313079 2020
45
CT texture analysis for the differentiation of papillary renal cell carcinoma subtypes. 61
32444891 2020
46
Differential diagnosis of chromophobe renal cell carcinoma and papillary renal cell carcinoma with dual-energy spectral computed tomography. 61
32088966 2020
47
Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. 61
33313134 2020
48
Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis. 61
33154194 2020
49
Papillary renal cell carcinoma with testicular and penile metastases: A case report and literature review. 61
33102061 2020
50
Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 61
33212488 2020

Variations for Renal Cell Carcinoma, Papillary, 1

ClinVar genetic disease variations for Renal Cell Carcinoma, Papillary, 1:

6 (show top 50) (show all 1165)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CTNNB1 NM_001904.4(CTNNB1):c.1374A>C (p.Glu458Asp) SNV other 438755 rs1553631848 3:41275208-41275208 3:41233717-41233717
2 MET NM_000245.4(MET):c.3682G>A (p.Asp1228Asn) SNV Pathogenic 13884 rs121913671 7:116423407-116423407 7:116783353-116783353
3 MET NM_000245.4(MET):c.3689A>G (p.Tyr1230Cys) SNV Pathogenic 13885 rs121913246 7:116423414-116423414 7:116783360-116783360
4 MET NM_000245.4(MET):c.3583C>G (p.Leu1195Val) SNV Pathogenic 13886 rs121913673 7:116422102-116422102 7:116782048-116782048
5 ATM ATM, IVS61DS, 2-BP INS, +2TA Insertion Pathogenic 3037
6 MET NM_000245.4(MET):c.3392T>C (p.Met1131Thr) SNV Pathogenic 13881 rs121913668 7:116418881-116418881 7:116778827-116778827
7 MET NM_000245.4(MET):c.3562G>T (p.Val1188Leu) SNV Pathogenic 13882 rs121913669 7:116422081-116422081 7:116782027-116782027
8 LOC107303340 NM_000551.3(VHL):c.548C>A (p.Ser183Ter) SNV Pathogenic 2215 rs5030823 3:10191555-10191555 3:10149871-10149871
9 LOC107303340 NM_001354723.2(VHL):c.*84_*90del Deletion Pathogenic 694389 rs1575932266 3:10191534-10191540 3:10149850-10149856
10 MET NM_000245.4(MET):c.3274G>A (p.Val1092Ile) SNV Pathogenic 186141 rs786202724 7:116417457-116417457 7:116777403-116777403
11 MTOR NM_004958.4(MTOR):c.3026G>A (p.Arg1009Gln) SNV Pathogenic 801436 rs778855567 1:11288729-11288729 1:11228672-11228672
12 MET NM_000245.4(MET):c.3281A>G (p.His1094Arg) SNV Pathogenic 13887 rs121913243 7:116417464-116417464 7:116777410-116777410
13 FBXW7 NM_001349798.2(FBXW7):c.1436G>C (p.Arg479Pro) SNV Likely pathogenic 376420 rs866987936 4:153247366-153247366 4:152326214-152326214
14 TP53 NM_000546.5(TP53):c.641A>G (p.His214Arg) SNV Likely pathogenic 376615 rs1057519992 17:7578208-7578208 17:7674890-7674890
15 PTEN NM_001304718.2(PTEN):c.-363C>G SNV Likely pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
16 PIK3CA NM_006218.4(PIK3CA):c.1625A>G (p.Glu542Gly) SNV Likely pathogenic 376475 rs1057519927 3:178936083-178936083 3:179218295-179218295
17 MTOR NM_004958.4(MTOR):c.6644C>T (p.Ser2215Phe) SNV Likely pathogenic 156703 rs587777894 1:11184573-11184573 1:11124516-11124516
18 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
19 PIK3CA NM_006218.4(PIK3CA):c.3141T>G (p.His1047Gln) SNV Likely pathogenic 376481 rs1057519932 3:178952086-178952086 3:179234298-179234298
20 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
21 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr) SNV Likely pathogenic 376129 rs587777894 1:11184573-11184573 1:11124516-11124516
22 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
23 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely pathogenic 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
24 MTOR NM_004958.4(MTOR):c.6643T>A (p.Ser2215Thr) SNV Likely pathogenic 376457 rs1057519917 1:11184574-11184574 1:11124517-11124517
25 PTEN NM_000314.8(PTEN):c.389G>T SNV Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
26 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
27 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
28 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
29 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Likely pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
30 NFE2L2 NM_006164.5(NFE2L2):c.85G>T (p.Asp29Tyr) SNV Likely pathogenic 376462 rs1057519920 2:178098960-178098960 2:177234232-177234232
31 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
32 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely pathogenic 376473 rs1057519927 3:178936083-178936083 3:179218295-179218295
33 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
34 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
35 FGFR3 NM_000142.5(FGFR3):c.1118A>G (p.Tyr373Cys) SNV Likely pathogenic 16342 rs121913485 4:1806099-1806099 4:1804372-1804372
36 FBXW7 NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln) SNV Likely pathogenic 376419 rs866987936 4:153247366-153247366 4:152326214-152326214
37 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
38 MTOR NM_004958.4(MTOR):c.6644C>T (p.Ser2215Phe) SNV Likely pathogenic 156703 rs587777894 1:11184573-11184573 1:11124516-11124516
39 FBXW7 NM_001349798.2(FBXW7):c.1436G>T (p.Arg479Leu) SNV Likely pathogenic 376421 rs866987936 4:153247366-153247366 4:152326214-152326214
40 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely pathogenic 376478 rs1057519929 3:178916854-178916854 3:179199066-179199066
41 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
42 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr) SNV Likely pathogenic 376129 rs587777894 1:11184573-11184573 1:11124516-11124516
43 NFE2L2 NM_006164.5(NFE2L2):c.86A>G (p.Asp29Gly) SNV Likely pathogenic 376464 rs1057519921 2:178098959-178098959 2:177234231-177234231
44 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
45 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Likely pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
46 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
47 NFE2L2 NM_006164.5(NFE2L2):c.85G>A (p.Asp29Asn) SNV Likely pathogenic 376463 rs1057519920 2:178098960-178098960 2:177234232-177234232
48 NFE2L2 NM_006164.5(NFE2L2):c.85G>C (p.Asp29His) SNV Likely pathogenic 376461 rs1057519920 2:178098960-178098960 2:177234232-177234232
49 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) SNV Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
50 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Papillary, 1:

73 (show all 15)
# Symbol AA change Variation ID SNP ID
1 MET p.Met1131Thr VAR_006286 rs121913668
2 MET p.Val1188Leu VAR_006287 rs121913669
3 MET p.Leu1195Val VAR_006288 rs121913673
4 MET p.Val1220Ile VAR_006289 rs121913670
5 MET p.Asp1228Asn VAR_006290 rs121913671
6 MET p.Asp1228His VAR_006291 rs121913671
7 MET p.Tyr1230Cys VAR_006292 rs121913246
8 MET p.Tyr1230His VAR_006293 rs121913247
9 MET p.Met1250Thr VAR_006294 rs121913245
10 MET p.Val1092Ile VAR_032485 rs786202724
11 MET p.His1094Leu VAR_032486
12 MET p.His1094Arg VAR_032487 rs121913243
13 MET p.His1094Tyr VAR_032488 rs121913244
14 MET p.His1106Asp VAR_032489
15 MET p.Tyr1230Asp VAR_032491

Cosmic variations for Renal Cell Carcinoma, Papillary, 1:

9 (show top 50) (show all 1659)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87583829 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.7085G>A p.R2362Q 9:107003322-107003322 9
2 COSM109100722 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.3803G>A p.R1268Q 9:107003322-107003322 9
3 COSM151995781 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 1:200407613-200407613 9
4 COSM93625940 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 1:200407613-200407613 9
5 COSM93623781 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.1985C>T p.P662L 1:200407613-200407613 9
6 COSM140954956 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 19:44131801-44131801 9
7 COSM140688909 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.*968G>T p.? 19:44131801-44131801 9
8 COSM85326448 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 19:44131801-44131801 9
9 COSM112895347 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3811G>T p.D1271Y 2:218642705-218642705 9
10 COSM105902090 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3811G>T p.D1271Y 2:218642705-218642705 9
11 COSM102023492 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.-23-6591T>C p.? 16:72957556-72957556 9
12 COSM87274574 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.2590T>C p.Y864H 16:72957556-72957556 9
13 COSM149269629 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.2590T>C p.Y864H 16:72957556-72957556 9
14 COSM89411866 ZBTB2 kidney,NS,carcinoma,papillary renal cell carcinoma c.931G>A p.E311K 6:151366135-151366135 9
15 COSM87436198 XPO4 kidney,NS,carcinoma,papillary renal cell carcinoma c.1299C>A p.F433L 13:20809842-20809842 9
16 COSM105761507 XPO4 kidney,NS,carcinoma,papillary renal cell carcinoma c.1299C>A p.F433L 13:20809842-20809842 9
17 COSM104888966 XPO1 kidney,NS,carcinoma,papillary renal cell carcinoma c.259A>G p.I87V 2:61522653-61522653 9
18 COSM104241577 XPO1 kidney,NS,carcinoma,papillary renal cell carcinoma c.259A>G p.I87V 2:61522653-61522653 9
19 COSM101982001 XPO1 kidney,NS,carcinoma,papillary renal cell carcinoma c.259A>G p.I87V 2:61522653-61522653 9
20 COSM136040220 XKR7 kidney,NS,carcinoma,papillary renal cell carcinoma c.1409C>T p.T470M 20:31997126-31997126 9
21 COSM108082894 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 9
22 COSM92179769 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 9
23 COSM94289415 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 9
24 COSM101580971 WDR89 kidney,NS,carcinoma,papillary renal cell carcinoma c.260C>A p.S87* 14:63599683-63599683 9
25 COSM145076301 WDR89 kidney,NS,carcinoma,papillary renal cell carcinoma c.260C>A p.S87* 14:63599683-63599683 9
26 COSM86850934 WDR89 kidney,NS,carcinoma,papillary renal cell carcinoma c.260C>A p.S87* 14:63599683-63599683 9
27 COSM90652475 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 3:10142092-10142092 9
28 COSM90649111 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-3275A>T p.? 3:10146512-10146512 9
29 COSM88295075 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.556G>T p.E186* 3:10149879-10149879 9
30 COSM88289113 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-2A>T p.? 3:10146512-10146512 9
31 COSM90649287 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.217C>T p.Q73* 3:10142064-10142064 9
32 COSM90655230 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.264G>C p.W88C 3:10142111-10142111 9
33 COSM88304452 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.443T>C p.F148S 3:10146616-10146616 9
34 COSM88294223 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.499C>T p.R167W 3:10149822-10149822 9
35 COSM88297043 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 9
36 COSM90650671 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-3261T>C p.? 3:10146526-10146526 9
37 COSM90671077 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.400T>G p.Y134D 3:10149846-10149846 9
38 COSM88292918 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.500G>A p.R167Q 3:10149823-10149823 9
39 COSM88288959 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.482G>A p.R161Q 3:10149805-10149805 9
40 COSM88292107 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.256C>T p.P86S 3:10142103-10142103 9
41 COSM90652409 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.234T>G p.N78K 3:10142081-10142081 9
42 COSM88293667 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.548C>A p.S183* 3:10149871-10149871 9
43 COSM90657935 VHL kidney,NS,carcinoma,renal cell c.362G>T p.C121F 3:10149808-10149808 9
44 COSM90649307 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 3:10142113-10142113 9
45 COSM88290223 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.341G>C p.G114A 3:10146514-10146514 9
46 COSM90655004 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.376C>T p.R126W 3:10149822-10149822 9
47 COSM88289297 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 3:10142113-10142113 9
48 COSM88290436 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 3:10146526-10146526 9
49 COSM88292022 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 3:10142092-10142092 9
50 COSM90653546 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.377G>A p.R126Q 3:10149823-10149823 9

Expression for Renal Cell Carcinoma, Papillary, 1

LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma, Papillary, 1 patients vs. healthy controls: 35 (show top 50) (show all 206)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 KCNJ1 potassium inwardly rectifying channel subfamily J member 1 Kidney - 9.09 0.000
2 FABP1 fatty acid binding protein 1 Kidney - 8.85 0.000
3 SLC12A1 solute carrier family 12 member 1 Kidney - 8.84 0.000
4 CALB1 calbindin 1 Kidney - 8.67 0.000
5 SCNN1G sodium channel epithelial 1 subunit gamma Kidney - 8.58 0.000
6 ALDOB aldolase, fructose-bisphosphate B Kidney - 8.53 0.000
7 CLDN8 claudin 8 Kidney - 8.44 0.000
8 HPD 4-hydroxyphenylpyruvate dioxygenase Kidney - 8.06 0.000
9 MUC15 mucin 15, cell surface associated Kidney - 7.91 0.000
10 KNG1 kininogen 1 Kidney - 7.82 0.000
11 EGF epidermal growth factor Kidney - 7.81 0.000
12 FXYD4 FXYD domain containing ion transport regulator 4 Kidney - 7.68 0.000
13 GSTA1 glutathione S-transferase alpha 1 Kidney - 7.61 0.000
14 NPHS2 NPHS2 stomatin family member, podocin Kidney - 7.60 0.000
15 G6PC glucose-6-phosphatase catalytic subunit Kidney - 7.50 0.000
16 SLC7A13 solute carrier family 7 member 13 Kidney - 7.32 0.000
17 HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 Kidney - 7.22 0.000
18 RALYL RALY RNA binding protein like Kidney - 7.10 0.000
19 HSD11B2 hydroxysteroid 11-beta dehydrogenase 2 Kidney - 7.08 0.000
20 FAM151A family with sequence similarity 151 member A Kidney - 7.08 0.000
21 DNASE1 deoxyribonuclease 1 Kidney - 7.00 0.000
22 TMEM52B transmembrane protein 52B Kidney - 6.94 0.000
23 KCNJ10 potassium inwardly rectifying channel subfamily J member 10 Kidney - 6.93 0.000
24 IRX2 iroquois homeobox 2 Kidney - 6.90 0.000
25 PVALB parvalbumin Kidney - 6.66 0.000
26 APOC1 apolipoprotein C1 Kidney + 6.64 0.000
27 SLC13A3 solute carrier family 13 member 3 Kidney - 6.60 0.000
28 SLC26A7 solute carrier family 26 member 7 Kidney - 6.51 0.000
29 SLC4A1 solute carrier family 4 member 1 (Diego blood group) Kidney - 6.51 0.000
30 TYRP1 tyrosinase related protein 1 Kidney - 6.46 0.000
31 UPB1 beta-ureidopropionase 1 Kidney - 6.39 0.000
32 CYP4A11 cytochrome P450 family 4 subfamily A member 11 Kidney - 6.38 0.000
33 SOST sclerostin Kidney - 6.35 0.000
34 HEPACAM2 HEPACAM family member 2 Kidney - 6.33 0.000
35 UMOD uromodulin Kidney - 6.21 0.000
36 SCNN1B sodium channel epithelial 1 subunit beta Kidney - 6.21 0.000
37 SLC22A6 solute carrier family 22 member 6 Kidney - 6.19 0.000
38 GC GC vitamin D binding protein Kidney - 6.19 0.000
39 MFSD4A major facilitator superfamily domain containing 4A Kidney - 6.19 0.000
40 PDE1A phosphodiesterase 1A Kidney - 6.18 0.002
41 GPC5 glypican 5 Kidney - 6.17 0.000
42 SFRP1 secreted frizzled related protein 1 Kidney - 6.11 0.000
43 MPPED2 metallophosphoesterase domain containing 2 Kidney - 6.07 0.000
44 HS6ST2 heparan sulfate 6-O-sulfotransferase 2 Kidney - 6.06 0.004
45 SLC22A8 solute carrier family 22 member 8 Kidney - 6.04 0.000
46 WNK4 WNK lysine deficient protein kinase 4 Kidney - 6.03 0.000
47 RHCG Rh family C glycoprotein Kidney - 6.01 0.000
48 CRHBP corticotropin releasing hormone binding protein Kidney - 5.99 0.000
49 EHF ETS homologous factor Kidney - 5.98 0.000
50 C16orf89 chromosome 16 open reading frame 89 Kidney - 5.97 0.000
Search GEO for disease gene expression data for Renal Cell Carcinoma, Papillary, 1.

Pathways for Renal Cell Carcinoma, Papillary, 1

Pathways related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 VHL TP53 PTEN PIK3CA NRAS MTOR
2
Show member pathways
13.93 VHL TP53 RHEB PTEN NRAS MTOR
3
Show member pathways
13.9 TP53 SF3B2 SF3B1 RHEB PTEN PRCC
4
Show member pathways
13.63 TP53 PIK3CA NRAS MTOR MET HRAS
5
Show member pathways
13.57 VHL TP53 PTEN PIK3CA NRAS MTOR
6
Show member pathways
13.5 TP53 PTEN NRAS MTOR MET HRAS
7
Show member pathways
13.43 TP53 PIK3CA NRAS MET HRAS FGFR3
8
Show member pathways
13.24 VHL TP53 RHEB MTOR ELOC CDKN2A
9
Show member pathways
13.21 TP53 PTEN PIK3CA MTOR MET FGFR3
10
Show member pathways
13.17 TP53 RHEB PTEN PIK3CA NRAS MTOR
11
Show member pathways
13.17 TP53 PTEN NRAS MTOR MET HRAS
12
Show member pathways
13.13 RHEB NRAS MTOR MET HRAS FGFR3
13
Show member pathways
13.1 TP53 RHEB PTEN PIK3CA NRAS MTOR
14
Show member pathways
13.08 TP53 RHEB PTEN MTOR ELOC CDKN2A
15
Show member pathways
13.06 TP53 RHEB PIK3CA NRAS MTOR HRAS
16
Show member pathways
13.03 RHEB PTEN PIK3CA NRAS MTOR MET
17
Show member pathways
12.99 PTEN PIK3CA NRAS MET HRAS ERBB2
18
Show member pathways
12.99 PTEN PIK3CA NRAS MTOR HRAS FGFR3
19
Show member pathways
12.98 TP53 RHEB PTEN PIK3CA NRAS MTOR
20
Show member pathways
12.88 TP53 PTEN PIK3CA NRAS NFE2L2 MTOR
21 12.87 TP53 NRAS MET HRAS FGFR3 ERBB2
22
Show member pathways
12.86 TP53 PTEN PIK3CA NRAS MTOR MET
23
Show member pathways
12.84 TP53 PTEN PIK3CA NRAS MTOR MET
24
Show member pathways
12.82 PIK3CA NRAS MET HRAS FGFR3
25
Show member pathways
12.82 TP53 PIK3CA NRAS HRAS CDKN2A ATM
26
Show member pathways
12.73 RHEB PIK3CA NRAS MTOR HRAS
27
Show member pathways
12.69 PTEN PIK3CA NRAS MTOR HRAS
28
Show member pathways
12.68 TP53 PIK3CA NRAS HRAS ERBB2
29
Show member pathways
12.66 TP53 PTEN PIK3CA NRAS MTOR MITF
30
Show member pathways
12.65 TP53 PTEN PIK3CA NRAS MTOR HRAS
31
Show member pathways
12.62 RHEB PTEN PIK3CA MTOR HRAS
32
Show member pathways
12.62 PTEN PIK3CA NRAS MTOR HRAS ERBB2
33
Show member pathways
12.6 PIK3CA NRAS MTOR MET HRAS
34
Show member pathways
12.59 TP53 RHEB PIK3CA MTOR HRAS
35
Show member pathways
12.57 TP53 PIK3CA NRAS MTOR MET HRAS
36
Show member pathways
12.57 TP53 RHEB PTEN PIK3CA NRAS MTOR
37
Show member pathways
12.56 PTEN PIK3CA NRAS MTOR HRAS
38
Show member pathways
12.54 TP53 RHEB PTEN PIK3CA MTOR MET
39
Show member pathways
12.53 PIK3CA NRAS MTOR MET HRAS FGFR3
40
Show member pathways
12.52 RHEB PIK3CA NRAS MTOR HRAS
41 12.49 TP53 PTEN PIK3CA NRAS MTOR MET
42
Show member pathways
12.48 RHEB PIK3CA MTOR FGFR3
43
Show member pathways
12.48 PIK3CA NRAS HRAS FGFR3
44 12.48 TP53 PTEN PIK3CA NRAS HRAS CDKN2A
45
Show member pathways
12.47 PTEN PIK3CA NRAS HRAS
46 12.47 TP53 PIK3CA MTOR ATM
47
Show member pathways
12.46 TP53 PTEN PIK3CA MTOR HRAS ERBB2
48
Show member pathways
12.45 TP53 PTEN CDKN2A ATM
49 12.44 TP53 PIK3CA NRAS MTOR MET HRAS
50
Show member pathways
12.43 PIK3CA NRAS HRAS ERBB2

GO Terms for Renal Cell Carcinoma, Papillary, 1

Cellular components related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 VHL TP53 SF3B2 SF3B1 PTEN PRCC
2 nucleoplasm GO:0005654 9.44 VHL TP53 SF3B2 SF3B1 PTEN PRCC

Biological processes related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 TP53 NFE2L2 MITF MET HRAS CDKN2A
2 apoptotic process GO:0006915 10.02 TP53 PTEN HRAS FGFR3 CDKN2A ATM
3 negative regulation of cell proliferation GO:0008285 9.99 VHL TP53 PTEN HRAS CDKN2A
4 protein phosphorylation GO:0006468 9.99 PIK3CA MTOR MET FGFR3 ERBB2 ATM
5 heart development GO:0007507 9.92 TP53 PTEN ERBB2 ATM
6 phosphorylation GO:0016310 9.91 PIK3CA MTOR MET FGFR3 ERBB2 CDKN2A
7 protein stabilization GO:0050821 9.88 VHL TP53 PTEN CDKN2A
8 MAPK cascade GO:0000165 9.85 NRAS MET HRAS FGFR3 ERBB2
9 protein autophosphorylation GO:0046777 9.84 MTOR FGFR3 ERBB2 ATM
10 liver development GO:0001889 9.8 PIK3CA MET HRAS
11 multicellular organism growth GO:0035264 9.79 TP53 MTOR ATM
12 cellular response to hypoxia GO:0071456 9.78 TP53 PTEN NFE2L2 MTOR
13 positive regulation of kinase activity GO:0033674 9.77 MET FGFR3 ERBB2
14 phosphatidylinositol 3-kinase signaling GO:0014065 9.67 PTEN PIK3CA ERBB2
15 anoikis GO:0043276 9.62 PIK3CA MTOR
16 Ras protein signal transduction GO:0007265 9.62 TP53 NRAS HRAS CDKN2A
17 negative regulation of cell size GO:0045792 9.61 PTEN MTOR
18 cellular response to gamma radiation GO:0071480 9.61 TP53 HRAS ATM
19 cell aging GO:0007569 9.58 TP53 MTOR HRAS
20 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.57 TP53 NFE2L2
21 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.56 TP53 NFE2L2
22 positive regulation of protein kinase B signaling GO:0051897 9.55 PIK3CA MTOR MET FGFR3 ERBB2
23 negative regulation of immature T cell proliferation in thymus GO:0033088 9.52 ERBB2 CDKN2A
24 replicative senescence GO:0090399 9.43 TP53 CDKN2A ATM
25 cell cycle arrest GO:0007050 9.43 TP53 RHEB MTOR HRAS CDKN2A ATM
26 positive regulation of gene expression GO:0010628 9.28 TP53 PTEN NFE2L2 MTOR MITF HRAS

Molecular functions related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.45 VHL TP53 SF3B2 SF3B1 RHEB PTEN
2 protein kinase activity GO:0004672 9.85 MTOR MET FGFR3 ERBB2 ATM
3 protein kinase binding GO:0019901 9.77 TP53 RHEB PTEN MTOR CDKN2A
4 protein-containing complex binding GO:0044877 9.65 NRAS MTOR HRAS ELOC ATM
5 nucleotide binding GO:0000166 9.61 RHEB PIK3CA NRAS MTOR MET HRAS
6 GDP binding GO:0019003 9.58 RHEB NRAS HRAS
7 1-phosphatidylinositol-3-kinase activity GO:0016303 9.43 PIK3CA ATM
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 MET FGFR3 ERBB2
9 MDM2/MDM4 family protein binding GO:0097371 9.32 TP53 CDKN2A
10 kinase activity GO:0016301 9.17 PIK3CA MTOR MET FGFR3 ERBB2 CDKN2A

Sources for Renal Cell Carcinoma, Papillary, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....